The companies will help customers develop new custom simplex or multiplex assays. Credit: Louis Reed on Unsplash.

Qiagen has collaborated with Niba Labs to provide customised digital PCR (dPCR) assay design services to customers in the biopharma industry.

Biopharma customers can use the dPCR offering to develop cell and gene therapies.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The partnership will enable the customers of the QIAcuity digital PCR instrument to leverage the combined expertise of Qiagen and Niba Labs for developing new custom simplex or multiplex assays to quantify nucleic acids and optimise existing qPCR assays for digital PCR use.

Niba Labs will involve in the assessment of the assay’s performance and validate them within good manufacturing practice.

Niba Labs chief scientific officer David Dobnik said: “We trust that our partnership with Qiagen will provide the biopharma industry with the most advanced analytical solutions to meet the evolving industry requirements and further advance their cell and gene therapy products.”

See Also:

Qiagen has also introduced the new CGT Viral Vector Lysis Kit, which allows a standardised workflow from cell lysates to quantify viral titers precisely for several serotypes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Designed to be used on the QIAcuity instrument, the new kit can determine viral genome titers in single and multiplex reactions and quantify them over a broad dynamic range with accuracy when integrated with the QIAcuity CGT dPCR assays.

These features make the assay suitable for drug development and quality control in manufacturing.

Qiagen Life Sciences PCR business head and vice-president Michael Scheffler said: “With the introduction of our CGT Viral Vector Lysis Kit, we aim to provide a streamlined protocol for AAV lysis that will bring standardisation to bioprocessing workflows and enhance Standard Operating Procedures, quality control and safety.

“In conjunction with our QIAcuity CGT assays, this kit allows for vector genome titration with remarkable accuracy, repeatability and robustness compared to current workflows.”